{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:10:51Z","timestamp":1762254651199,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pancreatic cancer represents a malignant neoplasm originating from pancreatic cells. The optimal approach to cancer treatment remains uncertain, lacking a definitive consensus. Here, we present a compelling case of a 49-year-old female with pancreatic head cancer with liver metastases, as identified by CT and confirmed by biopsy. PET-CT indicated widespread metastatic involvement. TACE therapy with gemcitabine and cisplatin was initiated, yielding a stable disease response. The patient\u2019s high PD-L1 expression prompted TACE-PD-1 monoclonal antibody combination therapy. Subsequent treatments, including ablation, sustained PD-1 immunotherapy, and consolidation TACE, culminated in a complete response, as evidenced by imaging and tumor marker dynamics. Our case underscores the potential of multifaceted strategies in managing aggressive pancreatic cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1275782","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T06:48:27Z","timestamp":1697006907000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Overcoming challenges in pancreatic cancer with liver metastases: a personalized therapeutic odyssey of TACE, ablation, and immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Ying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhouyu","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.3390\/app10207337","article-title":"Treatment strategy of transarterial chemoembolization for hepatocellular carcinoma","volume":"10","author":"Miyayama","year":"2020","journal-title":"Appl Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2017.11.014","article-title":"Transarterial chemoembolization in pancreatic adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and survival rates","volume":"18","author":"Vogl","year":"2018","journal-title":"Pancreatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2010.04.007","article-title":"Microwave tumor ablation: mechanism of action, clinical results, and devices","volume":"21","author":"Lubner","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i25.2578","article-title":"Microwave ablation of hepatocellular carcinoma","volume":"7","author":"Poggi","year":"2015","journal-title":"World J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jimed.2020.07.002","article-title":"In advanced pancreatic cancer: The value and significance of interventional therapy","volume":"3","author":"Hu","year":"2020","journal-title":"J Interv Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-2116","article-title":"PD-1\/PD-L1 expression in pancreatic cancer and its implication in novel therapies","volume":"94","author":"Mucileanu","year":"2021","journal-title":"Med Pharm Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s13193-011-0042-1","article-title":"Serum CA 19-9 as a biomarker for pancreatic cancer-A comprehensive review","volume":"2","author":"Ballehaninna","year":"2011","journal-title":"Indian J Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPOPNPLLCYR07H","article-title":"The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center","volume":"138","author":"Passerini","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29242","article-title":"A preoperative serum signature of CEA+\/CA125+\/CA19-9\u2009\u2265\u20091000 U\/mL indicates poor outcome to pancreatectomy for pancreatic cancer","volume":"136","author":"Liu","year":"2015","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-013-2389-9","article-title":"CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer","volume":"17","author":"Luo","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.241","article-title":"Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status","volume":"62","author":"Masson","year":"1990","journal-title":"Br J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1275782\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T06:48:33Z","timestamp":1697006913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1275782\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2023.1275782"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1275782","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"article-number":"1275782"}}